124 related articles for article (PubMed ID: 30543720)
21. Plasma levels and diagnostic utility of macrophage-colony stimulating factor, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 as tumor markers in cervical cancer patients.
Zajkowska M; Zbucka-Krętowska M; Sidorkiewicz I; Lubowicka E; Gacuta E; Szmitkowski M; Chrostek L; Ławicki S
Tumour Biol; 2018 Jul; 40(7):1010428318790363. PubMed ID: 30052166
[TBL] [Abstract][Full Text] [Related]
22. Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
El-Attar NI; Gaefar HA
Egypt J Immunol; 2007; 14(2):111-21. PubMed ID: 20306663
[TBL] [Abstract][Full Text] [Related]
23. [The plasma levels and diagnostic utility of granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage - colony stimulating factor (GM-CSF) in patients with I and II stage of breast cancer].
Ławicki S; Czygier M; Wojtukiewicz M; Szmitkowski M
Przegl Lek; 2009; 66(7):365-9. PubMed ID: 20043577
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of pretreatment serum levels of VEGF and its receptors, IL- 8, and their prognostic value in type I and II endometrial cancer patients.
Kotowicz B; Fuksiewicz M; Jonska-Gmyrek J; Berezowska A; Radziszewski J; Bidzinski M; Kowalska M
PLoS One; 2017; 12(10):e0184576. PubMed ID: 28991928
[TBL] [Abstract][Full Text] [Related]
25. The prognostic value of vascular endothelial growth factors (VEGFs)-A and -B and their receptor, VEGFR-1, in invasive breast carcinoma.
Mylona E; Alexandrou P; Giannopoulou I; Liapis G; Sofia M; Keramopoulos A; Nakopoulou L
Gynecol Oncol; 2007 Mar; 104(3):557-63. PubMed ID: 17150246
[TBL] [Abstract][Full Text] [Related]
26. Biological variations in plasma VEGF and VEGFR-1 may compromise their biomarker value in colorectal cancer.
Svendsen MN; Brünner N; Christensen IJ; Ytting H; Bentsen C; Lomholt AF; Nielsen HJ
Scand J Clin Lab Invest; 2010 Nov; 70(7):503-11. PubMed ID: 20873967
[TBL] [Abstract][Full Text] [Related]
27. Biomarker triplet NAMPT/VEGF/HER2 as a de novo detection panel for the diagnosis and prognosis of human breast cancer.
Zhu Y; Guo M; Zhang L; Xu T; Wang L; Xu G
Oncol Rep; 2016 Jan; 35(1):454-62. PubMed ID: 26531769
[TBL] [Abstract][Full Text] [Related]
28. Comparison of serum VEGF and its soluble receptor sVEGFR1 with serum cell-free DNA in patients with breast tumor.
El Tarhouny S; Seefeld M; Fan AX; Hahn S; Holzgreve W; Zhong XY
Cytokine; 2008 Oct; 44(1):65-9. PubMed ID: 18691902
[TBL] [Abstract][Full Text] [Related]
29. Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.
Czekierdowski A
Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):113-31. PubMed ID: 12898913
[TBL] [Abstract][Full Text] [Related]
30. The usefulness of determining the serum concentrations of vascular endothelial growth factor (VEGF) and its soluble receptor type 2 (sVEGF-2) in the differential diagnosis of adrenal incidentalomas.
Foltyn W; Strzelczyk J; Marek B; Kajdaniuk D; Siemińska L; Rosiek V; Kos-Kudła B
Endokrynol Pol; 2012; 63(1):22-8. PubMed ID: 22378094
[TBL] [Abstract][Full Text] [Related]
31. Comparison of (18)F-fluorodeoxyglucose PET/CT findings with vascular endothelial growth factors and receptors in colorectal cancer.
Kocael A; Vatankulu B; Şimşek O; Cengiz M; Kemik A; Kocael P; Halaç M; Sönmezoğlu K; Ulualp K
Tumour Biol; 2016 Mar; 37(3):3871-7. PubMed ID: 26476536
[TBL] [Abstract][Full Text] [Related]
32. Significance of vascular endothelial growth factor, interleukin-18 and nitric oxide in patients with breast cancer: correlation with carbohydrate antigen 15.3.
Metwally FM; El-mezayen HA; Ahmed HH
Med Oncol; 2011 Dec; 28 Suppl 1():S15-21. PubMed ID: 20725807
[TBL] [Abstract][Full Text] [Related]
33. Peripheral blood concentrations of vascular endothelial growth factor and its soluble receptors (R1 and R2) in patients with adrenal cortex tumours treated by surgery.
Jurczyńska J; Stepień T; Lawnicka H; Stepień H; Krupiński R; Kołomecki K; Kuzdak K; Komorowski J
Endokrynol Pol; 2009; 60(1):9-13. PubMed ID: 19224499
[TBL] [Abstract][Full Text] [Related]
34. Selected angiogenic factors in plasma of patients with lower limb symptomatic peripheral arterial disease: preliminary report.
Wieczór R; Gadomska G; Góralczyk B; Stankowska K; Budzyński J; Fabisiak J; Suppan K; Pulkowski G; Rość D
Int Angiol; 2015 Dec; 34(6):545-51. PubMed ID: 25394959
[TBL] [Abstract][Full Text] [Related]
35. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia.
Wierzbowska A; Robak T; Wrzesień-Kuś A; Krawczyńska A; Lech-Marańda E; Urbańska-Ryś H
Eur Cytokine Netw; 2003; 14(3):149-53. PubMed ID: 14656688
[TBL] [Abstract][Full Text] [Related]
36. Hematopoietic cytokines as tumor markers in breast malignancies. A multivariate analysis with ROC curve in breast cancer patients.
Ławicki S; Będkowska GE; Wojtukiewicz M; Szmitkowski M
Adv Med Sci; 2013; 58(2):207-15. PubMed ID: 23846151
[TBL] [Abstract][Full Text] [Related]
37. A comparison of plasma versus histologic indices of angiogenic markers in breast cancer.
Caine GJ; Lip G; Zanetto U; Maheshwari M; Stonelake PS; Blann AD
Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):382-8. PubMed ID: 18091379
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic Value of Serum Concentration and Integrity of Circulating Cell-Free DNA in Breast Cancer: A Comparative Study With CEA and CA15-3.
Tang Z; Li L; Shen L; Shen X; Ju S; Cong H
Lab Med; 2018 Oct; 49(4):323-328. PubMed ID: 29701836
[TBL] [Abstract][Full Text] [Related]
39. [Assessment of pro- and antiangiogenic factors blood serum concentrations in patients with hormonal inactive adrenal tumors].
Korzeniewska M; Kołomecki K; Stepień H; Naze M; Stepień T; Kuzdak K
Endokrynol Pol; 2005; 56(1):39-44. PubMed ID: 16335673
[TBL] [Abstract][Full Text] [Related]
40. Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy women: useful as diagnostic tools?
Granato AM; Nanni O; Falcini F; Folli S; Mosconi G; De Paola F; Medri L; Amadori D; Volpi A
Breast Cancer Res; 2004; 6(1):R38-45. PubMed ID: 14680499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
